Intrathecal chitotriosidase and the outcome of multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 5, 2006, Pages 551-557

  Sotgiu, Stefano ^a,c   Barone, R ^b   Arru, G ^a   Fois, M L ^a   Pugliatti, M ^a   Sanna, A ^a   Rosati, G ^a   Musumeci, S ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cerebrospinal fluid; Chitotriosidase; Macrophage; Multiple sclerosis; Prognosis

Indexed keywords

ALBUMIN; CHITOTRIOSIDASE; BETA N ACETYLHEXOSAMINIDASE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; RECURRENT DISEASE; REGRESSION ANALYSIS; REMISSION; AGED; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DISABILITY; HOSPITALIZATION; IMMUNOBLOTTING; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; OBSERVATION; OUTCOME ASSESSMENT;

ADULT; AGED; CASE-CONTROL STUDIES; DISABILITY EVALUATION; FEMALE; HEXOSAMINIDASES; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 33847611360     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070614     Document Type: Article

References (24)

1. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004; 101: 11064-69.
2. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of MS lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
3. Kornek B, Lassmann H. Neuropathology of multiple sclerosis: new concepts. Brain Res Bull 2003; 61: 321-26.
4. Hendriks JA, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Rev 2005; 48: 185-95.
5. Furlan R, Rovaris M, Martinelli Boneschi F, Khademi M, Bergami A, Gironi M et al. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol 2005; 165: 192-200.
6. Boot RG, Renkema H, Strijland A, van Zonneveld AJ, Aerts JMFG. Cloning of cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995; 270: 26252-56.
7. Renkema GH, Boot RG, Au F, Donker-Koopman WE, Strijland A, Muijsers AO et al. Chitotriosidase, a chitinase, and the 39 kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251: 504-509.
8. Bouzas L, Guinarte JC, Tutor JC. Chitotriosidase activity in plasma and mononuclear and polymorphonuclear leukocyte populations. J Clin Lab Anal 2003; 17: 271-75.
9. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998; 273: 25680-85.
10. Malaguarnera L, Simpore J, Prodi DA, Angius A, Sassu A, Persico I et al. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions. Genes Immun 2003; 4: 570-74.
11. Hollak CEM, van Weely S, van Oers MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest 1994; 93: 1288-92.
12. Barone R, Malaguarnera L, Angius A, Musumeci S. Plasma chitotriosidase activity in patients with beta-thalassemia. Am J Hematol 2003; 72: 285-86.
13. Artieda M, Cenarro A, Ganan A, Jerico I, Gonzalvo C, Casado JM et al. Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. Arterioscler Thromb Vasc Biol 2003; 23: 1645-52.
14. Palasik W, Fiszer U, Lechowicz W, Czartoryska B, Krzesiewicz M, Lugowska A. Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. Eur Neurol 2005; 53: 188-93.
15. Barone R, Simpore J, Malaguarnera L, Pignatelli S, Musumeci S. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clin Chim Acta 2003; 331: 79-85.
16. Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 1997; 42: 613-21.
17. Czartoryska B, Fiszer U, Lugowska A. Chitotriosidase activity in cerebrospinal fluid as a marker of inflammatory process in neurological diseases. J Lab Med (Berlin) 2001; 25: 77-81
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
19. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
20. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
21. Link H. The cerebrospinal fluid in multiple sclerosis. In Swash M, Oxbury J eds. Textbook of neurology. Churchill Livingstone, 1992: 1128-39.
22. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
23. Trapp BD, Bö L, Mörk S, Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 1999; 98: 49-56.
24. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, Villarrubia N et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-94.